Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes (IAI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00700219
Recruitment Status : Unknown
Verified July 2010 by ProteoGenix, Inc..
Recruitment status was:  Recruiting
First Posted : June 18, 2008
Last Update Posted : July 21, 2010
Sponsor:
Collaborator:
Obstetrix Medical Group
Information provided by:
ProteoGenix, Inc.

Brief Summary:
The purpose of this study is to collect clinical specimens and corresponding clinical data to develop a non-invasive test for detection of intra-amniotic infection and prediction of preterm birth in women and intact amniotic membranes. The specimens collected will be used to develop a specific biomarker panel and algorithm using immunoassays for optimal detection of intra-amniotic infection in women with preterm labor and intact amniotic membranes.

Condition or disease
Intra-amniotic Infection

Detailed Description:

Intra-amniotic infection (IAI) is an acute bacterial infection of the amniotic fluid and intrauterine contents during pregnancy and occurs in 4% to 10% of all deliveries (Newton, ER., 1993. Newton, ER, et al., 1989. Soper, DE, et al., 1989). IAI is an important cause of maternal and neonatal morbidity. Identifying and appropriately treating women with IAI is, therefore, a major obstetrical challenge.

Intrauterine infection may occur early in pregnancy and remain undetected for a prolonged period, thus exposing the fetus to the effects of infection/inflammation for a considerable period. Ideally, an early diagnosis of IAI is important to allow timely treatment and intervention. Unfortunately, the early diagnosis is difficult because the clinical signs and symptoms of IAI may occur late in the course of the infection and are neither sensitive nor specific. Therefore, to avoid a delay in diagnosis a high degree of suspicion and the appropriate use of adjunctive laboratory tests are warranted.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 900 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Development of a Non-invasive Test to Detect Intra-amniotic Infection and Predict Preterm Birth in Women Presenting With Preterm Labor and and Intact Amniotic Membranes
Study Start Date : June 2008
Estimated Primary Completion Date : September 2010
Estimated Study Completion Date : September 2010

Group/Cohort
1
Women presenting in preterm labor with intact amniotic membranes



Primary Outcome Measures :
  1. Performance of immunoassay panel to detect intra-amniotic infection in target population. [ Time Frame: Presentation to delivery ]

Biospecimen Retention:   Samples Without DNA
Cervical-vaginal Fluid, Amniotic Fluid, Maternal Serum, Neonatal Cord Blood, Maternal Urine, Placental and Umbilical Cord Tissues


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women presenting to labor and delivery with signs and symptoms of preterm labor and documented intact amntiotic membranes
Criteria

Inclusion Criteria:

  • Subject is greater than or equal to 18 years of age
  • Subject has singleton gestation
  • Subject has fetus with gestational age greater than or equal to 22 0/7 weeks and less than or equal to 36 6/7 weeks
  • Subject has documented intact amniotic membranes
  • Subject's care provider plans to or has performed an amniocentesis procedure
  • Subject has had evidence of spontaneous preterm labor as evidenced by documented regular uterine contractions (greater than or equal to four per hour, or if less than 26 weeks gestation, cramping or backache) and one or more of the following:

    1. Progressive cervical change with cervical dilation of greater than or equal to 2 cm
    2. Effacement of greater than or equal to 50%
    3. Cervical length of less than or equal to 30 mm via transvaginal ultrasound
    4. Positive fetal fibronectin test

Exclusion Criteria:

  • Subject has documented ruptured amniotic membranes
  • Subject has fetus with major fetal anomaly or chromosomal aneuploidy
  • Subject has medical indication for preterm birth (e.g. pre-eclampsia)
  • Subject is unable to provide written informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00700219


Contacts
Layout table for location contacts
Contact: Desiree Hollemon, MSN, MPH 503-748-4067 hollemon@proteogenix.com
Contact: Durlin Hickok, MD 503-748-4067 hickok@proteogenix.com

Locations
Show Show 21 study locations
Sponsors and Collaborators
ProteoGenix, Inc.
Obstetrix Medical Group
Investigators
Layout table for investigator information
Principal Investigator: Andrew Combs, MD, PhD Obstetrix Medical Group of California
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Durlin Hickok, MD, MPH, ProteoGenix, Inc.
ClinicalTrials.gov Identifier: NCT00700219    
Other Study ID Numbers: PGX01-OBX0006
First Posted: June 18, 2008    Key Record Dates
Last Update Posted: July 21, 2010
Last Verified: July 2010
Keywords provided by ProteoGenix, Inc.:
Preterm Labor
Preterm Birth
Intra-amniotic Infection
Pregnancy
Women
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications